EyeGene KRX:185490KOSDAQ
아이진 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, EyeGene reported revenue of ₩1.3bn, up 52.7% year on year, and an operating loss of ₩3.9bn. EyeGene (아이진) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals 4 quarters of losses Screener
EyeGene quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.3bn | +52.7% | −₩3.9bn margin −294.8% | −₩3.8bn |
| Q1 2026 | ₩1.3bn | +55.6% | −₩3.5bn margin −277.7% | −₩3.6bn |
| Q4 2025 derived | ₩774m | -41.0% | −₩3.3bn | −₩12.1bn |
| Q3 2025 | ₩1.1bn | +14.4% | −₩1.6bn margin −150.1% | −₩1.6bn |
| Q2 2025 | ₩877m | +56.3% | −₩2.5bn margin −279.6% | −₩2.5bn |
| Q1 2025 | ₩818m | +56.3% | −₩2.5bn | −₩3.0bn |
| Q4 2024 derived | ₩1.3bn | +8.1% | −₩2.4bn margin −180.8% | −₩2.7bn |
| Q3 2024 | ₩960m | +76.8% | −₩3.6bn | −₩3.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
EyeGene top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest EyeGene news Korean headlines
No articles yet.